{"hq_id":"hq-p-wer-000084","name":"Natural Rubber Latex Glove Allergy in Healthcare Workers (NRL Type I IgE Hypersensitivity, Anaphylaxis, Cornstarch Powder Aerosolization)","category":{"primary":"workplace_hazard","secondary":"latex_allergy","tags":["latex","natural rubber","NRL","glove allergy","Type I hypersensitivity","IgE","anaphylaxis","healthcare worker","cornstarch powder","Hevea brasiliensis"]},"product_tier":"WER","overall_risk_level":"high","description":"Natural rubber latex (NRL) gloves manufactured from Hevea brasiliensis tree sap contain over 200 polypeptides, of which at least 15 are recognized allergens (Hev b 1 through Hev b 15) capable of triggering IgE-mediated Type I hypersensitivity reactions ranging from contact urticaria to life-threatening anaphylaxis. The healthcare latex allergy epidemic peaked in the 1990s when prevalence among healthcare workers reached 8-17%, driven by increased glove use during the HIV/AIDS era and the introduction of high-protein powdered latex gloves. Cornstarch donning powder acts as an airborne carrier for latex proteins — aerosolized latex-protein-laden powder particles (5-50 micrometers) are inhaled by all personnel in the clinical environment, sensitizing even non-glove-wearers. The FDA banned powdered medical gloves in 2017 (21 CFR 801.437), which dramatically reduced new sensitization rates. However, previously sensitized workers face career-limiting consequences: cross-reactive allergies to foods (banana, avocado, kiwi, chestnut — the latex-fruit syndrome) and risk of anaphylaxis from incidental latex contact in medical devices, tourniquets, and medication vial stoppers.","synthesis":{"derived_risk_level":"moderate","synthesis_confidence":0.82,"synthesis_method":"compound_composition","context_used":"human_adult","context_source":"default","exposure_modifier":1,"vulnerability_escalated":false,"escalation_reason":null,"compounds_resolved":1,"compounds_total":1,"synthesis_date":"2026-03-27","synthesis_version":"1.0.0"},"hazard_summary":{"sensitive_populations":"healthcare workers with >5 years of daily glove use, atopic individuals, spina bifida patients (repeated surgical latex exposure from birth), laboratory workers, dental professionals","overall_risk":"high","primary_concerns":["Type I anaphylaxis risk from IgE-mediated latex protein hypersensitivity — can be fatal","8-17% prevalence among healthcare workers during powdered glove era","Cornstarch powder aerosolizes latex proteins, sensitizing non-glove-wearers in the clinical environment","Latex-fruit syndrome cross-reactivity (banana, avocado, kiwi) affects 30-50% of latex-allergic individuals"],"exposure_routes":"Dermal (direct glove contact with skin). Inhalation (aerosolized latex-protein-laden cornstarch powder). Mucosal (surgical glove contact with mucosal surfaces triggers systemic allergic response)."},"exposure":{"routes":["dermal","inhalation","mucosal"],"contact_types":["dermal_direct","inhalation_aerosolized","mucosal_contact"],"users":["healthcare_worker","nurse","surgeon","dental_professional","laboratory_worker"],"duration":"chronic","frequency":"daily_occupational","scenarios":["Nurse develops contact urticaria from repeated daily latex glove use over months to years","Surgeon experiences intraoperative anaphylaxis from latex glove contact with mucosal tissue during surgery","Non-glove-wearing staff sensitized by inhaling cornstarch-aerosolized latex proteins in clinical environment","Previously sensitized worker experiences anaphylaxis from latex tourniquet, catheter, or medication vial stopper"],"notes":"NRL allergy prevalence: 8-17% healthcare workers (1990s peak); 1-3% general population. Hev b allergens: Hev b 5 (most clinically relevant), Hev b 6.02 (hevein, cross-reacts with foods), Hev b 1, Hev b 3. Latex-fruit syndrome: 30-50% of latex-allergic individuals cross-react with banana, avocado, kiwi, chestnut (shared chitinase and beta-1,3-glucanase epitopes). FDA powdered glove ban: 21 CFR 801.437 effective January 2017 — eliminated the primary aerosolization route for latex proteins. Post-ban: new sensitization rates decreased 50-70% in hospital systems. Remaining risk: non-glove latex devices (tourniquets, catheters, vial stoppers, balloon tips)."},"consumer_guidance":{"usage_warning":"Healthcare facilities should transition to non-latex (nitrile or vinyl) glove stocks. Previously sensitized workers must carry epinephrine auto-injectors and wear medical alert identification. Notify all healthcare providers of latex allergy before any medical procedure — latex is present in tourniquets, catheters, IV ports, and medication vial stoppers. Be aware of latex-fruit syndrome cross-reactivity with banana, avocado, kiwi, and chestnut.","safer_alternatives":["Nitrile examination gloves (no NRL proteins; dominant market choice post-2017)","Synthetic polyisoprene surgical gloves (latex-free, closest tactile feel to NRL)","Vinyl (PVC) gloves for low-risk tasks","Neoprene gloves for chemical handling without latex exposure"]},"regulatory":{"applicable_regulations":[{"jurisdiction":"USA","regulation":"FDA Ban on Powdered Medical Gloves — 21 CFR 801.437","citation":"21 CFR 801.437; FDA Final Rule 81 FR 91722 (December 19, 2016); effective January 18, 2017","requirements":"FDA banned powdered surgeon's gloves, powdered patient examination gloves, and absorbable powder for lubricating surgeon's gloves. Products deemed adulterated under Section 501(c) of the FD&C Act. Ban applies to all manufacturers and importers. Non-powdered NRL gloves remain legal if labeled with latex allergen warnings per 21 CFR 801.437.","compliance_status":null,"effective_date":"2017-01-18","enforcing_agency":"FDA Center for Devices and Radiological Health","penalties":null,"source_ref":null}],"certifications":[],"labeling":{"required_disclosures":[],"prop65_warning":{"required":null,"chemicals":[],"endpoint":null,"notes":null},"ghs_labeling":{"required":null,"signal_word":null,"pictograms":[],"hazard_statements":[],"notes":null},"hidden_ingredients":{"trade_secret_protected":null,"categories_hidden":[],"estimated_count":null,"known_concerns":null,"notes":null},"notes":null},"recalls":[],"regulatory_gap":null,"notes":null},"lifecycle":{"recyclable":false,"disposal_guidance":"Dispose of latex gloves in regular medical waste or biohazard containers per facility protocol. Non-latex alternatives generate equivalent waste.","hazardous_waste":false,"expected_lifespan":"Single use; 15-45 minutes per pair typical clinical use"},"formulation":{"form":"varies","key_ingredients":[],"certifications":[]},"materials":{"common":[],"concerning":[],"preferred":[]},"compound_composition":[{"hq_id":"hq-c-mix-000040","compound_name":null,"role":"allergen_source","typical_concentration":"NRL protein content 100-1000 ug/g in gloves; Hev b allergens trigger IgE at sensitization threshold ~0.6 ug/m3 airborne"}],"identifiers":{"common_names":["natural rubber latex glove allergy in healthcare workers (nrl type i ige hypersensitivity, anaphylaxis, cornstarch powder aerosolization)"],"aliases":[],"manufacturer":null,"brands":[]},"brand_examples":[],"sources":[{"type":"expert_curation","name":"ALETHEIA Safety Database","date":"2026-03-26"}],"meta":{"schema_version":"4.0.0","last_updated":"2026-03-26","timestamp":"2026-05-01T14:25:07.764Z"}}